258 related articles for article (PubMed ID: 8398291)
1. 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy--a randomised study.
Jantunen IT; Muhonen TT; Kataja VV; Flander MK; Teerenhovi L
Eur J Cancer; 1993; 29A(12):1669-72. PubMed ID: 8398291
[TBL] [Abstract][Full Text] [Related]
2. Serotonin receptor antagonists in prophylaxis of acute and delayed emesis induced by moderately emetogenic, single-day chemotherapy: a randomized study.
Yalçin S; Tekuzman G; Baltali E; Ozişik Y; Barişta I
Am J Clin Oncol; 1999 Feb; 22(1):94-6. PubMed ID: 10025391
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
[TBL] [Abstract][Full Text] [Related]
4. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
Perez EA
J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
[TBL] [Abstract][Full Text] [Related]
5. Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost.
Abali H; Celik I
Cancer Invest; 2007; 25(3):135-9. PubMed ID: 17530482
[TBL] [Abstract][Full Text] [Related]
6. Prevention of delayed emesis by a single intravenous bolus dose of 5-HT3-receptor-antagonist in moderately emetogenic chemotherapy.
Massidda B; Ionta MT
J Chemother; 1996 Jun; 8(3):237-42. PubMed ID: 8808724
[TBL] [Abstract][Full Text] [Related]
7. Antiemetic efficacy of three serotonin antagonists during high-dose chemotherapy and autologous stem cell transplantation in malignant lymphoma.
Slabý J; Trnený M; Procházka B; Klener P
Neoplasma; 2000; 47(5):319-22. PubMed ID: 11130251
[TBL] [Abstract][Full Text] [Related]
8. Ondansetron and tropisetron in the control of nausea and vomiting in children receiving combined cancer chemotherapy.
Stiakaki E; Savvas S; Lydaki E; Bolonaki I; Kouvidi E; Dimitriou H; Kambourakis A; Kalmanti M
Pediatr Hematol Oncol; 1999; 16(2):101-8. PubMed ID: 10100270
[TBL] [Abstract][Full Text] [Related]
9. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis.
Jordan K; Hinke A; Grothey A; Schmoll HJ
Support Care Cancer; 2005 Jan; 13(1):26-31. PubMed ID: 15668744
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis.
Jordan K; Hinke A; Grothey A; Voigt W; Arnold D; Wolf HH; Schmoll HJ
Support Care Cancer; 2007 Sep; 15(9):1023-33. PubMed ID: 17205281
[TBL] [Abstract][Full Text] [Related]
11. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
12. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
13. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
14. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
15. '... setron': are 5-HT3 receptor antagonists different?
Aapro MS
Eur J Cancer; 1993; 29A(12):1655. PubMed ID: 8398287
[No Abstract] [Full Text] [Related]
16. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
[TBL] [Abstract][Full Text] [Related]
17. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
18. Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin.
Mantovani G; Macciò A; Curreli L; Lampis B; Ghiani M; Bianchi A; Contu P
Oncol Rep; 1998; 5(1):273-80. PubMed ID: 9458381
[TBL] [Abstract][Full Text] [Related]
19. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
20. A comparative study of intravenous granisetron versus intravenous and oral ondansetron in the prevention of nausea and vomiting associated with moderately emetogenic chemotherapy.
Park JO; Rha SY; Yoo NC; Kim JH; Roh JK; Min JS; Kim BS; Chung HC
Am J Clin Oncol; 1997 Dec; 20(6):569-72. PubMed ID: 9391542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
